Money moves in silence. Download 2025 State of Venture Report: a data-driven analysis of active funds, unicorn, and family offices
About usSign in
Status
ACTIVE
Global HQ
Boston, United States
Countries of investment
  • United States
  • United Kingdom
  • China
  • Switzerland
  • Canada
  • Denmark
  • France
  • Germany
  • Italy
Investment stages
  • Series A
  • Series B
  • Series C
  • Growth
Industries
  • Biotechnology
  • Life Sciences
  • Healthcare
  • Pharmaceuticals
About
RA Capital Management advances evidence-based investing across public and private healthcare and life sciences, managing $12.6B in assets to fund novel therapies from early-stage biotech to clinical programs, leveraging integrated scientific diligence, data-driven analysis, and a long-term perspective on breakthrough patient impact.
Min check size
$100K
Max check size
$75M
Fund size
NPS

Investment Thesis

RA Capital Management drives life sciences innovation by funding breakthrough biotechnology, therapeutics, and healthcare platforms, combining deep scientific expertise with rigorous research and collaborative capital deployment.
Lead investor
Co Invest
Number of exits
Preferred contact method

Manager's Experience

Managed by life sciences investors and scientists with deep expertise in biotechnology, drug development, and healthcare innovation across public and private markets.

RA Capital Management Contacts Information

Primary contact

Secondary contact

Team

Peter Kolchinsky - Managing Partner

Rajeev Shah - Managing Partner

Derek DiRocco - Partner

Matthew Hammond - Partner

Jeremy Lack - Partner

Andrew Levin - Partner

Josh Resnick - Partner

Jake Simson - Partner

Laura Stoppel - Partner

Mario Barro - Head of Infectious Disease Team

Portfolio

Moderna

Beam Therapeutics

Relay Therapeutics

Fund number
Vintage Year
Net Internal Rate of Return
Investment Multiple
Capital Allocation
Management Fee
Carried Interest
AUM
Follow-on Investments
Graduation Rate
Write-Off Ratio
Last profile update timestamp